MaxCyte, Inc. Total Voting Rights (9363Q)

TIDMMXCT TIDMTTM

RNS Number : 9363Q

MaxCyte, Inc.

03 March 2021

MaxCyte, Inc.

("MaxCyte" or the "Company")

Total Voting Rights

Gaithersburg, Maryland - 3 March 2021: MaxCyte (LSE: MXCT, MXCL, MXCN), the global cell-based medicines and life sciences company, announces that pursuant to its block admission facility, details of which were announced on 2 May 2017, it has recently issued 3,300 shares of common stock, $0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options.

The new Common Stock will rank pari passu with the existing shares of common stock of the Company. The total issued stock capital of the Company, as at 28 February 2021, following the recent issue of the new Common Stock, is 84,559,246 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 74,329,157 ; the number of restricted shares of Common Stock trading under the symbol 'MXCL' is 9,900,089 a nd the number of restricted shares of Common Stock trading under the symbol 'MXCN' will be 330,000.

For further information, please contact:

 
 
  MaxCyte Inc. 
    Doug Doerfler, Chief Executive Officer 
    Ron Holtz, Chief Accounting Officer       [phone] 
 
    Nominated Adviser and Joint Corporate 
    Broker 
    Panmure Gordon 
    Emma Earl 
    Freddy Crossley 
    Corporate Broking 
    Rupert Dearden                             [phone] 
 
    Joint Corporate Broker 
    Numis Securities Limited 
    James Black 
    Duncan Monteith                            [phone] 
   Joint Corporate Broker 
 
    Stifel Nicolaus Europe Limited 
    Healthcare Investment Banking 
    Nicholas Moore / Ben Maddison / 
    Samira Essebiyea 
    Corporate Broking 
    Nick Adams                                 [phone] 
 

About MaxCyte

MaxCyte is a world-leading provider of cell-engineering platform technologies that drives the next--generation of cell and gene-editing therapies. The Company's technology, which is designed to make a meaningful difference for patients, is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licenses have been granted for more than 140 cell therapy programs, with more than 100 licensed for clinical use, and the Company has now entered into 12 clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US.

For more information, visit www.maxcyte.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRDKBBNKBKBCNK

(END) Dow Jones Newswires

March 03, 2021 02:00 ET (07:00 GMT)